Phase 3 Recruiting Network
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Sites in Florida: - The Watson Clinic — Lakeland, Florida
Phase 3 Recruiting Network
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of som…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06807437
Sites in Florida: - Moffitt Cancer Center at SouthShore — Ruskin, Florida
- Moffitt Cancer Center-International Plaza — Tampa, Florida
- Moffitt Cancer Center - McKinley Campus — Tampa, Florida
- Moffitt Cancer Center — Tampa, Florida
- Moffitt Cancer Center at Wesley Chapel — Wesley Chapel, Florida
Phase 2, Phase 3 Recruiting Industry
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…
Sponsor: Pfizer
NCT ID: NCT06989437
Sites in Florida: - Mayo Clinic Pharmacy — Jacksonville, Florida
- Mayo Clinic — Jacksonville, Florida
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in Florida: - Investigative Site US072 — Fort Myers, Florida
- Investigative Site US083 — Jacksonville, Florida
- Investigative Site US075 — Miami, Florida
- Investigative Site US074 — St. Petersburg, Florida
- Investigative Site US073 — West Palm Beach, Florida
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Sites in Florida: - Mayo Clinic - Florida — Jacksonville, Florida
- AdventHealth Orlando — Orlando, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Sites in Florida: - Baptist MD Anderson Cancer Institute — Jacksonville, Florida
- Baptist Health Medical Group Oncology — Miami, Florida
- Mount Sinai Medical Center - Miami Beach — Miami Beach, Florida
Phase 3 Recruiting Industry
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Sponsor: RenovoRx
NCT ID: NCT03257033
Sites in Florida: - 21st Century Oncology — Fort Myers, Florida
- Miami Cancer Center — Miami, Florida
- Sarasota Memorial Health Care System — Sarasota, Florida
- Moffitt Cancer Center — Tampa, Florida
- ASCLEPES Research Centers — Weeki Wachee, Florida
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07252232
Sites in Florida: - Mayo Clinic — Jacksonville, Florida
- University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center — Miami, Florida
- Florida Cancer Specialists — St. Petersburg, Florida
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Sponsor: Immuneering Corporation
NCT ID: NCT07562152
Sites in Florida: - Hematology Oncology Associates of the Treasure Coast — Port Saint Lucie, Florida
- Florida Cancer Specialists - South — Sarasota, Florida
- Florida Cancer Specialists - North — St. Petersburg, Florida
- Florida Cancer Specialists - East — West Palm Beach, Florida
Phase 3 Recruiting Industry
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…
Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Sites in Florida: - University of Miami — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07491445
Sites in Florida: - H Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07621718
Sites in Florida: - Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first li…
Sponsor: Eleison Pharmaceuticals LLC.
NCT ID: NCT01954992
Sites in Florida: - Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
Sponsor: Quercis Pharma AG
NCT ID: NCT06861088
Sites in Florida: - Clavis Medical, LLC — Miami Lakes, Florida
Phase 2 Recruiting NIH
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in Florida: - AdventHealth Altamonte — Altamonte Springs, Florida
- AdventHealth Celebration — Celebration, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- AdventHealth Kissimmee — Kissimmee, Florida
Phase 2 Recruiting Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Florida: - Schulze Family Foundation Cancer Clinic - Bonita Health Center — Bonita Springs, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- Regional Cancer Center-Lee Memorial Health System — Fort Myers, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
Phase 2 Recruiting Academic/Other
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…
Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in Florida: - Ohio State University-Telemedicine — Jacksonville, Florida
- Ohio State University-Telemedicine — Miami, Florida
- Ohio State University-Telemedicine — Orlando, Florida
- Ohio State University Telemedicine — Tallahassee, Florida
- Ohio State University-Telemedicine — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Florida: - Florida Cancer Specialists — Fort Myers, Florida
- Mayo Clinic (Florida) — Jacksonville, Florida
- Cancer Specialists of North Florida — Jacksonville, Florida
- Florida Cancer Specialists — Orlando, Florida
- Florida Cancer Specialists — Sarasota, Florida
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Florida: - Mayo Clinic Cancer Center — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Florida: - Florida Cancer Specialists — Sarasota, Florida
- Moffitt Cancer Center and Research Institute — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in Florida: - Moffitt Cancer Center — Tampa, Florida
Phase 2 Recruiting Industry
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Sponsor: Verastem, Inc.
NCT ID: NCT07644559
Sites in Florida: - Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06922591
Sites in Florida: - Mayo Clinic Jacksonville — Jacksonville, Florida
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Florida: - Florida Cancer Specialists - South — Fort Myers, Florida
- Florida Cancer Specialists - Lake Nona — Orlando, Florida
- Florida Cancer Specialists - North — St. Petersburg, Florida
- Florida Cancer Specialists - East — West Palm Beach, Florida
Phase 1, Phase 2 Recruiting Industry
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-del…
Sponsor: Bayer
NCT ID: NCT06914128
Sites in Florida: - Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona — Orlando, Florida